No Recurrence-Free Survival Benefit With Adjuvant Pembrolizumab in Hepatocellular Carcinoma

1. KEYNOTE-937 trial compared pembrolizumab to placebo in HCC patients. 2. No significant differences in recurrence-free survival were noted. 3. Median recurrence-free survival: 46.7 months (pembrolizumab) vs 45.5 months (placebo). 4. 60% of patients experienced treatment-related adverse events. 5. Treatment showed common side effects: pruritus, rash, hypothyroidism. 6. Study underscores unmet need for effective adjuvant therapies for HCC. 7. Randomized 959 patients; 1:1 allocation between treatments.